Ryvu Therapeutics SA (RVU) — Cash Flow Reinvestment Rate

Latest as of December 2022: 3.31x

Ryvu Therapeutics SA (RVU) has a Cash Flow Reinvestment Rate of 3.31x as of December 2022, reinvesting zł198.08 Million (capex zł4.22 Million plus investments zł-193.87 Million) from operating cash flow of zł59.92 Million. Explore Ryvu Therapeutics SA capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

3.31x
(Capex + Investments) / Operating CF

Total Reinvested

zł198.08 Million
Capex + Investments

Operating Cash Flow

zł59.92 Million
PLN

Capital Expenditures

zł4.22 Million
PLN

Ryvu Therapeutics SA Cash Flow Reinvestment Rate (2017–2022)

Historical reinvestment intensity for Ryvu Therapeutics SA across 2 annual periods. Also explore Ryvu Therapeutics SA balance sheet assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Ryvu Therapeutics SA (2017–2022)

Year-by-year capital reinvestment analysis for Ryvu Therapeutics SA. For live market cap and broader valuation context, see Ryvu Therapeutics SA stock valuation.

Year Reinvestment Rate Total Reinvested (PLN) Operating CF Capex YoY Change
2022 0.47x zł9.98 Million zł21.32 Million zł9.29 Million ▼ -85.8%
2017 3.30x zł36.26 Million zł10.98 Million zł21.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow